title: Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging.
abstract: We have tested the T helper cell (TH) potential of asymptomatic, HIV seropositive (HIV+) patients, using an in vitro assay for IL-2 production. Peripheral blood leukocytes (PBL) from 74 HIV+ patients and 70 HIV- control donors were tested for TH function when stimulated with influenza A virus (FLU), tetanus toxoid (TET), HLA alloantigens (ALLO), or PHA. Of the HIV+ patients, four different response patterns were observed: (a) patients who responded to all four stimuli (16%); (b) patients who were selectively unresponsive to FLU and TET, but responded to ALLO and PHA (54%); (c) patients who were unresponsive to FLU, TET, or ALLO, but responsive to PHA (16%); and (d) patients who failed to respond to any of these stimuli (14%). Our results indicate a time-dependent progression from a stage responsive to all four stimuli to a stage unresponsive to any of the stimuli tested, progressing in the order outlined above. The earliest TH defect is the loss of responses to FLU and TET, indicating a selective defect in CD4+ MHC self-restricted TH function. The later loss of ALLO and PHA IL-2 responses suggests more severe TH dysfunction involving both CD4+ and CD8+ T cells. None of these patterns of TH unresponsiveness in asymptomatic HIV+ individuals were correlated with CD4+ cell numbers nor with Walter Reed staging criteria. This study indicates that the in vitro TH assay used can detect multiple stages of immune dysregulation early in the course of HIV infection and raises the possibility that staging of HIV+ patients should include in vitro TH functional analyses of the type described here.
authors.affiliation: Experimental Immunology Branch, National Cancer Institute, Bethesda, Maryland 20892.
authors.forename: M
authors.initials: M
authors.lastname: Clerici
authors.forename: N I
authors.initials: NI
authors.lastname: Stocks
authors.forename: R A
authors.initials: RA
authors.lastname: Zajac
authors.forename: R N
authors.initials: RN
authors.lastname: Boswell
authors.forename: D R
authors.initials: DR
authors.lastname: Lucey
authors.forename: C S
authors.initials: CS
authors.lastname: Via
authors.forename: G M
authors.initials: GM
authors.lastname: Shearer
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology; D000956:Antigens, Viral / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000473:pathology; D002455:Cell Division; D002478:Cells, Cultured; D006679:HIV Seropositivity / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D006968:Hypersensitivity, Delayed; D009980:Influenza A virus / Q000276:immunology; D007376:Interleukin-2 / Q000096:biosynthesis; D007958:Leukocyte Count; D010835:Phytohemagglutinins / Q000494:pharmacology; D012882:Skin Tests; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*; D013745:Tetanus Toxoid / Q000494:pharmacology; D013997:Time Factors
chemical_list: D000956:Antigens, Viral; D006680:HLA Antigens; D007376:Interleukin-2; D010835:Phytohemagglutinins; D013745:Tetanus Toxoid